Cargando…
Rare upper gastrointestinal hemorrhage of cetuximab: A case report
RATIONALE: cetuximab, an epidermal growth factor receptor inhibitor, is a targeted therapeutic regimen of colorectal cancers. Several common adverse effects have been found, such as cutaneous or gastrointestinal toxicity. However, according to the articles had been published, upper gastrointestinal...
Autores principales: | Duan, Shi-Jie, Gao, Zi-Ming, Wang, Peng-Liang, Gong, Bao-Cheng, Huang, Han-Wei, Luo, Lei, Wang, Xin, Xing, Ya-Nan, Xu, Hui-Mian, Liu, Fu-Nan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758247/ https://www.ncbi.nlm.nih.gov/pubmed/29390545 http://dx.doi.org/10.1097/MD.0000000000009391 |
Ejemplares similares
-
A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Bi-Cheng, et al.
Publicado: (2019) -
Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell
por: Yang, Xiaohui, et al.
Publicado: (2020) -
Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
por: Tai, Cheng-Jeng, et al.
Publicado: (2016) -
Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016) -
Widespread Metastasis to the Stomach 10 Years After Primary Breast Cancer: A case report and review of the literature
por: Fu, Ji-Xin, et al.
Publicado: (2020)